Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

RATIONAL DEVELOPMENT OF A COMBINATION NANOPARTICLE ADJUVANT FOR INFLUENZA.

Project Number
75N93019C00037-0-9999-1

Contact PI/Project Leader
ORR, MARK

Awardee Organization
HDT BIO CORPORATION

Description

Abstract Text

Highly pathogenic avian H7N9 influenza, which has killed 615 people since 2013, is poised to cause a **pandemic** in a worldwide population that has no pre-existing immunity. Current H7 vaccines are insufficiently immunogenic without the addition of adjuvants, but responses to these adjuvanted vaccines are not durable and may not be protective against newly emergent viral strains. The project will evaluate a combination adjuvant designed to augment the immunity and efficacy of an H7 influenza immunogen. The target adjuvant profile includes promotion of a broader response, augmentation of durable immunity, and, protective efficacy against H7N9 avian influenza. This SBIR will support formulation activities and the evaluation of vaccine efficacy in an animal model.

Public Health Relevance Statement

Data not available.

NIH Spending Category

Biodefense Bioengineering Emerging Infectious Diseases Immunization Infectious Diseases Influenza Nanotechnology Pneumonia & Influenza Prevention Vaccine Related

Project Terms

Adjuvant Agonist Animal Model Antigens Avian Influenza Birds Cellular Immunity Development Formulation Humoral Immunities Immunity Influenza Influenza A Virus, H7N9 Subtype Pathogenicity Phase Population Property Small Business Innovation Research Grant TLR7 gene Technology Vaccines Viral design immunogenic influenza virus vaccine nanoparticle **pandemic** disease **pandemic** influenza protective efficacy response vaccine efficacy vaccine evaluation

Details

Contact PI/ Project Leader

Name
ORR, MARK

Title

Contact
Email not available

Other PIs

Not Applicable

Program Official

Name

Contact
Email not available

Thank you for your feedback!

Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

RATIONAL DEVELOPMENT OF A COMBINATION NANOPARTICLE ADJUVANT FOR INFLUENZA.

Project Number
75N93019C00037-0-9999-1

Contact PI/Project Leader
ORR, MARK

Awardee Organization
HDT BIO CORPORATION

UNITED STATES (US)

Other Information

FOA

Study Section

Fiscal Year
2019

Award Notice Date

Administering Institutes or Centers
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

DUNS Number
080798860

CFDA Code

Project Start Date **01-September-2019**

Project End Date **31-August-2021**

Budget Start Date

Budget End Date

Project Funding Information for 2019

Total Funding
$599,629

Direct Costs
$0

Indirect Costs
$0

Year	Funding IC	
2019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$599,629

NIH Categorical Spending

Click here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$599,629	Biodefense; Bioengineering; Emerging Infectious Diseases; Immunization; Infectious Diseases; Influenza; Nanotechnology; Pneumonia & Influenza; Prevention; Vaccine Related

Sub Projects

No Sub Projects information available for 75N93019C00037-0-9999-1

Publications

No Publications available for 75N93019C00037-0-9999-1

Thank you for your feedback!

Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

RATIONAL DEVELOPMENT OF A COMBINATION NANOPARTICLE ADJUVANT FOR INFLUENZA.

Project Number
75N93019C00037-0-9999-1

Contact PI/Project Leader
ORR, MARK

Awardee Organization
HDT BIO CORPORATION

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 75N93019C00037-0-9999-1

Clinical Studies

No Clinical Studies information available for 75N93019C00037-0-9999-1

News and More

Related News Releases

No news release information available for 75N93019C00037-0-9999-1

History

No Historical information available for 75N93019C00037-0-9999-1

Similar Projects

No Similar Projects information available for 75N93019C00037-0-9999-1